Black Hawk Acquisition Corp SEC filings BKHA
Black Hawk Acquisition Corp has 117 filings in SEC EDGAR's recent list, going back to Dec 21, 2023. Its latest annual report, Form 10-K, was filed on Mar 6, 2026 for the period ended Nov 30, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 6, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on November 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Sep 25, 2026 | — |
| EFFECT | Filing | Sep 17, 2026 | — |
| NT 10-Q | Filing | Apr 14, 2026 | Feb 28, 2026 |
| NT 10-K | Filing | Mar 2, 2026 | Nov 30, 2025 |
| DEL AM | Filing | Dec 29, 2025 | — |
| NT 10-Q | Filing | Oct 15, 2025 | Aug 31, 2025 |
| DRS/A | Filing | Sep 23, 2025 | — |
| DRS/A | Filing | Aug 4, 2025 | — |
| DRS | Filing | Jun 12, 2025 | — |
| DEFR14A | Filing | Jun 10, 2025 | — |
| 425 | Filing | Apr 29, 2025 | — |
| CERT | Filing | Mar 21, 2024 | — |
| EFFECT | Filing | Mar 20, 2024 | — |
| 8-A12B | Filing | Mar 20, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| CORRESP | Letter to the SEC | Feb 23, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 21, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2024 | — |
| DRS | Filing | Dec 21, 2023 | — |
Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BKHA (Nasdaq), BKHAR (Nasdaq), BKHAU (Nasdaq)
- Fiscal year ends
- November 30
- Headquarters
- Danville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2000775
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.